#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Virtual Echocardiography as a Potential Screening Tool for the Diagnosis of Primary Pulmonary Hypertension

Primary pulmonary hypertension disease is associated with a poor prognosis. Early diagnosis and the implementation of specific therapy are necessary to improve patients' prospects. In the near future, virtual echocardiography, which has shown good results in published studies, may become a valuable screening tool.
Source: Pulmonary hypertension (CTEPH, PAH) 10. 3. 2021

News How to Prevent and Treat Thromboembolic Disease in Cancer Patients

Malignancy is one of the risk factors for the development of thromboembolic disease (TED). Venous thromboembolism is considered the second most common cause of death in cancer patients, with the top cause being the cancer itself. Therefore, optimal treatment and timely prevention of these complications is very important.
Source: Thromboprophylaxis 6. 3. 2021

News Thromboprophylaxis with Enoxaparin Reduces Mortality in Patients Hospitalized with COVID-19

Severe acute respiratory syndrome caused by COVID-19 is associated with a hypercoagulable state and an increased risk of thrombotic events. Since the beginning of the pandemic, thromboprophylaxis has been recommended for these patients despite initial insufficient evidence. In the fall of 2020, an observational study was published confirming the beneficial effect of enoxaparin on reducing mortality and the risk of ICU admission in patients with severe COVID-19.
Source: Thromboprophylaxis 11. 3. 2021

News Benefit of ixazomib in patients with relapsed/refractory multiple myeloma in routine clinical practice

The results of treating relapsed or refractory multiple myeloma in real-world routine clinical practice were published by a broad team of Czech experts in the journal BMC Cancer.
Source: Hematologic Malignancies 10. 3. 2021

News Is Baricitinib Suitable for Long-Term Treatment of Rheumatoid Arthritis?

The nature of rheumatoid arthritis requires effective and long-term treatment. The current analysis of data from the long-term extension RA-BEYOND reveals the potential of baricitinib in maintaining low disease activity and remission with long-term use.
Source: Biological Treatment 12. 3. 2021

News Invasive Pulmonary Aspergillosis –⁠ A Common Accompanying Infection in Patients with Severe or Critical Course of COVID-19

Findings based on a literature review conducted and published in September 2020 show the occurrence of invasive pulmonary aspergillosis (IPA) in 19.6–33.3% of patients with a severe or critical course of COVID-19. The authors provide several important insights for clinical practice, including recommended management of therapy for these patients.
Source: Anti-Infectives 8. 2. 2021

News Therapy with Cyclosporine in the Context of the Coronavirus Pandemic

The rapid spread of the SARS-CoV-2 virus and the associated COVID-19 disease pandemic raises concerns about possible risks associated with immunosuppressive treatment of autoimmune diseases. Specifically, does the use of cyclosporine increase the risk of infection, or does it act protectively?
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 14. 4. 2021

News Safety Profile of Antiemetic Therapy in Patients Preparing for Hematopoietic Stem Cell Transplantation

An observational study conducted at a university clinic in Barcelona investigated the safety of the fixed combination of palonosetron and netupitant in patients preparing for hematopoietic stem cell transplantation.
Source: Antiemetic Therapy 15. 2. 2021

News Intravenous Fixed Combination NEPA in the Prevention of Chemotherapy-Induced Vomiting

Summary data from several studies were used by the authors of the following analysis to evaluate the efficacy of the intravenous and oral forms of the fixed combination NEPA (netupitant/fosnetupitant + palonosetron) administered with dexamethasone in preventing chemotherapy-induced vomiting based on cisplatin or anthracycline and cyclophosphamide (AC).
Source: Antiemetic Therapy 15. 2. 2021

News Do antiglaucoma drugs induce inflammation and irritation on the eye surface? Results of a 2-year randomized study

Eye drops for glaucoma treatment may contain preservatives responsible for eye irritation and possibly chronic inflammation. The study presented below is the first to compare the profile of inflammatory cytokines and eye irritation in patients using topical antiglaucoma drugs with and without preservatives.
Source: Treatment of Glaucoma 18. 2. 2021

News Antiglaucoma Eye Drops with Preservatives –⁠ Higher Likelihood of Glaucoma Surgery?

A recently published French study sought to answer the question of whether there is a connection between the presence of preservatives in antiglaucoma eye drops and the probability of undergoing glaucoma surgery.
Source: Treatment of Glaucoma 18. 2. 2021

News Quantitative CT as a New Tool for Evaluating COPD in Alpha-1 Antitrypsin Deficiency

For such a rare hereditary disorder as alpha-1 antitrypsin deficiency (AATD), we have so far used functional tests as the main tool for monitoring the progression of lung disease. Now we are moving further. Quantitative CT examination is even more advantageous in terms of assessing clinical development.
Source: Deficiency of Alpha-1-Antitrypsin 18. 2. 2021

News Efficacy of Dabigatran on Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation

The direct thrombin inhibitor dabigatran has shown interesting efficacy in a smaller clinical study in patients with atrial fibrillation and a thrombus in the left atrial appendage. Chinese authors evaluated the results of anticoagulant therapy using transthoracic and transesophageal echocardiography.
Source: Anticoagulant Treatment 22. 2. 2021

News Intravenous Thrombolysis in Ischemic Stroke Patients on Dabigatran Treatment

What are the outcomes of performing intravenous thrombolysis in patients with acute ischemic stroke after reversing the anticoagulant effect of dabigatran with idarucizumab? The answer is provided by a data analysis from real-world clinical practice in stroke centers, published by Czech authors.
Source: Anticoagulant Treatment 18. 2. 2021

News Do ACE Inhibitors Have a Protective Effect in People with COVID-19?

Although the COVID-19 pandemic has not lasted even a year, a number of studies have already been processed, examining the influence of various factors on the morbidity and mortality of patients. The presented meta-analysis investigated the influence of ACE inhibitors on the mortality of patients with this disease.
Source: ACE inhibitory 25. 2. 2021

1 … 26 27 28 29 30 … 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#